ZG-2291

ZG-2291 is a potent, orally active, and selective FIH inhibitor that functions by inducing a conformational change in a key catalytic tyrosine. It has demonstrated efficacy in promoting thermogenesis and improving metabolic parameters in preclinical models of obesity, such as ob/ob mice, making it a valuable research tool for studying obesity-related metabolic diseases.